NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose
- Completed
- Dec 6, 2013
- 1 min read
Updated: Jun 13, 2022
NCT01775553: Phase 2: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
The purpose of this study is to determine the safety and activity of the investigational drug known as carfilzomib in the treatment of multiple myeloma (MM) when it is given at doses above the usual dose after the standard dosing has become ineffective. The other purpose of this study is to understand what causes the multiple myeloma to become resistant to carfilzomib and whether this can be overcome in the laboratory.
Sponsor
Ajai Chari
Collaborator
Amgen
United States, New York
Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT01775553
Official Title: Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
First Posted : January 25, 2013
Click here for details on ClinicalTrials.gov
Am J Hematol; 2020 Feb
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2
653. Myeloma: Therapy, excluding Transplantation: Poster II| December 3, 2015
Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Location
United States, New York